Cart
sales@molnova.com
Home - Products - MAPK/ERK Signaling - p38 MAPK - SSK1

SSK1

CAS No. 2629250-69-5

SSK1( —— )

Catalog No. M34948 CAS No. 2629250-69-5

SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 327 Get Quote
5MG 510 Get Quote
10MG 736 Get Quote
25MG 1095 Get Quote
50MG 1463 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    SSK1
  • Note
    Research use only, not for human use.
  • Brief Description
    SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
  • Description
    SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted proagent attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis.
  • In Vitro
    Cell Proliferation Assay Cell Line:Primary mouse fibroblasts,Concentration:0.5?μM,Incubation Time:12 hours, 24 hours, 36 hours, 48 hours, 72 hours Result:Both p38 MAPK and MKK3/MKK6 were activated by phosphorylation in senescent cells.
  • In Vivo
    Animal Model:Mice (3-6-month-old) were subjected to transtracheal injection of Bleomycin Dosage:0.5 mg/kg Administration:Intraperitoneally injection; two days every week; for four weeks Result:SSK1 significantly reduced the percentage of SA-β-gal-positive cells in lung by 3.8-fold compared with t hat in vehicle-treated lung-injured mice
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    p38 MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2629250-69-5
  • Formula Weight
    788.61
  • Molecular Formula
    C31H34F2N4O18
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 200 mg/mL (253.61 mM; Ultrasonic )
  • SMILES
    [H][C@]1(O[C@H](CO)[C@@H](O)C1(F)F)n1ccc(NC(=O)OCc2ccc(O[C@@H]3O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]3OC(C)=O)c(c2)[N+]([O-])=O)nc1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Pamapimod

    A potent, selective, orally bioavailable p38α MAPK inhibitor with Kd of 0.2 nM.

  • EO-1606

    EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.

  • LY2228820 dimesylate

    LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor p38 MAPK with IC50 of 5.3 and 3.2 nM for p38α and p38β, respectively.

Sign In Join Free